-
Electronic (PDF)
-
Site License
-
Enterprisewide
Competitor Analysis: Antibody-Drug Conjugates (ADC) 2013
La Merie Publishing, April 2013, Pages: 104
The present Competitive Intelligence Report about Antibody-Drug Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the field of tumor targeting antibodies conjugated via a linker with a drug payload for treatment of cancer as of April 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The emerging therapeutic class of antibody-drug conjugates (ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one of the two major technologies (auristatin and maytansin derivatives) have paved the way for a total of further 33 ADCs in clinical studies and further six ADCs in IND enabling studies. Adcetris posted US sales of US$ 138 mln in 2012 and with the start of marketing of Kadcyla, sales of this therapeutic class are expected to reach blockbuster size. New linker and toxic payload technologies are being developed and the first representative ADCs from the new technologies are approaching clinical proof of concept testing.
The report includes a compilation of currently active projects in research and development of antibody-drug conjugates and other immunoconjugates in oncology. In addition, the report lists company-specific R&D pipelines of antibody-drug conjugates. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. Antibody-Drug Conjugates (ADC)
Adcetris Pipeline 5
Antibody-Drug Conjugates with Auristatin Derivatives 9
Antibody-Drug Conjugates with Pyrrolobenzodiazepine (PBD) Derivatives 21
Kadcyla Pipeline 23
Antibody-Drug Conjugates with Maytansinoid Derivatives 25
Antibody-Drug Conjugates with Irinotecan Derivatives 32
Antibody-Drug Conjugates with Doxorubicin 34
Antibody-Drug Conjugates with Calicheamicin Derivatives 35
Antibody-Drug Conjugates with Duocarmycin Derivative 37
Antibody-Drug Conjugates with Various Drugs 38
Antibody-Drug Conjugates with Not Disclosed Drugs 42
Other Immunoconjugates 46
Antibody-Drug Conjugates: R&D Collaboration Agreements 49
Antibody-Drug Conjugates: Licensing Agreements 51
2. Corporate ADC R&D Pipelines
Abbvie 53
AbGenomics 53
ADC Therapeutics 54
Aeterna Zentaris 55
Allozyne 57
Ambrx 58
Amgen 59
Amunix 30
Astellas Pharma (Agensys) 61
Bayer HealthCare Pharmaceuticals 63
Biotest 64
Celldex Therapeutics 65
Centrose 66
Cytoguide 67
Daiichi Sankyo 68
Eli Lilly 68
Endo Pharmaceuticals 69
Esperance Pharmaceuticals 69
Genmab 70
GlaxoSmithKline 71
Heidelberg Pharma (a Wilex company) 71
ImmunoGen 72
Immunomedics 75
Intellect Neurosciences 77
Menarini 78
Merck 78
Merrimack Pharmaceuticals 79
Mersana Therapeutics 80
Millenium Pharmaceuticals (a Takeda Pharmaceutical Co company) 82
Novartis 82
Oxford Biotherapeutics 83
Pfizer 84
Polytherics 87
Progenics Pharmaceuticals 88
Roche (Genentech) 89
Sanofi 95
Seattle Genetics 96
Soricimed Biopharma 105
Spirogen 106
Synthon Biopharmaceuticals 107
- Abbvie
- AbGenomics
- ADC Therapeutics
- Aeterna Zentaris
- Allozyne
- Ambrx
- Amgen
- Amunix
- Astellas Pharma (Agensys)
- Bayer HealthCare Pharmaceuticals
- Biotest
- Celldex Therapeutics
- Centrose
- Cytoguide
- Daiichi Sankyo
- Eli Lilly
- Endo Pharmaceuticals
- Esperance Pharmaceuticals
- Genmab
- GlaxoSmithKline
- Heidelberg Pharma (a Wilex company)
- ImmunoGen
- Immunomedics
- Intellect Neurosciences
- Menarini
- Merck
- Merrimack Pharmaceuticals
- Mersana Therapeutics
- Millenium Pharmaceuticals (a Takeda Pharmaceutical Co company)
- Novartis
- Oxford Biotherapeutics
- Pfizer
- Polytherics
- Progenics Pharmaceuticals
- Roche (Genentech)
- Sanofi
- Seattle Genetics
- Soricimed Biopharma 1
- Spirogen 1
- Synthon Biopharmaceuticals
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
